Triple Inhaled Therapy at Two Glucoco... - Lung Conditions C...

Lung Conditions Community Forum

56,245 members66,869 posts

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.

2greys profile image
2 Replies

Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA) for chronic obstructive pulmonary disease (COPD) have been studied at single dose levels of inhaled glucocorticoid, but studies at two dose levels are lacking.

Triple therapy with twice-daily budesonide (at either the 160-μg or 320-μg dose), glycopyrrolate, and formoterol resulted in a lower rate of moderate or severe COPD exacerbations than glycopyrrolate–formoterol or budesonide–formoterol.

nejm.org/doi/suppl/10.1056/...

Written by
2greys profile image
2greys
To view profiles and participate in discussions please or .
Read more about...
2 Replies
2greys profile image
2greys

For those who have trouble with PDF files:

Triple therapy, including glucocorticoid at either of two dose levels, is beneficial for moderate-to-very severe chronic obstructive pulmonary disease (COPD), according to a study published online June 24 in the New England Journal of Medicine.

Klaus F. Rabe, M.D., Ph.D., from the German Center for Lung Research in Grosshansdorf, and colleagues conducted a 52-week, phase 3 trial to assess the efficacy and safety of triple therapy at two dose levels of inhaled glucocorticoid in patients with moderate-to-very severe COPD and at least one exacerbation in the previous year. A total of 8,509 patients were randomly assigned to receive either twice-daily inhaled doses of triple therapy (inhaled glucocorticoid [320 or 160 µg], a long-acting muscarinic antagonist [LAMA; glycopyrrolate], and a long-acting β2-agonist [LABA; formoterol]) or one of two dual therapies (glycopyrrolate plus formoterol or budesonide plus formoterol) in a 1:1:1:1 ratio.

The researchers found that the annual rates of moderate or severe exacerbations were 1.08 and 1.07 in the 320- and 160-µg budesonide triple therapy groups, respectively; 1.42 in the glycopyrrolate-formoterol group; and 1.24 in the budesonide-formoterol group. Compared with glycopyrrolate-formoterol or budesonide-formoterol, the rate was significantly lower with 320-µg glucocorticoid triple therapy (rate ratios, 0.76 and 0.87, respectively). Similarly lower rates were seen with 160-µg glucocorticoid triple therapy (rate ratios, 0.75 and 0.86, respectively).

"Our findings show the benefits of triple therapy with a budesonide-glycopyrrolate-formoterol combination over dual therapy with a LAMA-LABA or an inhaled glucocorticoid-LABA combination," the authors write.

The study was funded by AstraZeneca.

Not for me I can't even do dual /combi.

I still take all my meds individually. I can control dose better that way avoiding side affects that can occur with combi.

Its the formeterol I can only take one dose a day to avoid excessive muscle cramps.

Good for those that can tolerate the triple therapy.

Not what you're looking for?

You may also like...

Inhaled steroids may not work for half of asthma patients.

Inhaled corticosteroids have been the mainstay of treatment for persistent asthma for decades. A...
2greys profile image

LABA and LAAs Update to research

Elderly patients suffering from chronic obstructive pulmonary disease (COPD) who are treated with...
martin1945 profile image

Restructure at work & Moderate copd

I was diagnosed with copd in 2008 and it is now at a moderate stage. I will be 59 in May. I have...
Beatrix12 profile image

Anxious

I am new, in fact I have never done this sort of thing before! I have mild/moderate copd! I worry...
Katy75 profile image